Use of antiarrhythmic compounds for reducing post-infarction...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/34 (2006.01) A61K 31/343 (2006.01) A61K 45/06 (2006.01)

Patent

CA 2249481

The use of benzofuran derivatives having antiarrhythmic activity, particularly amiodarone or dronedarone, or a pharmaceutically acceptable salt thereof, for preparing pharmaceutical compositions capable of reducing cardiac-related mortality, particularly arrhythmia-related mortality and sudden death in patients who have a reduced left ventricular function following a myocardial infarction but do not have a disturbed cardiac rhythm requiring an antiarrhythmic treatment, is disclosed.

L'invention a pour objet l'utilisation de dérivés de benzofuranne à activité antiarythmique en particulier l'amiodarone ou la dronédarone, ou d'un sel pharmaceutiquement acceptable de ces dérivés, pour la préparation de compositions pharmaceutiques destinées à réduire la mortalité d'origine cardiaque en particulier la mortalité cardiaque d'origine arythmique et la mort subite chez des patients présentant une fonction ventriculaire gauche réduite après infarctus du myocarde, sans troubles du rythme nécessitant un traitement antiarythmique.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Use of antiarrhythmic compounds for reducing post-infarction... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of antiarrhythmic compounds for reducing post-infarction..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of antiarrhythmic compounds for reducing post-infarction... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1957462

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.